Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 282

1.

Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.

Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Höfler H, Langer R.

Hum Pathol. 2013 May;44(5):829-36. doi: 10.1016/j.humpath.2012.08.005. Epub 2012 Nov 14.

PMID:
23158210
[PubMed - indexed for MEDLINE]
2.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
[PubMed - indexed for MEDLINE]
3.

Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.

Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY.

J Thorac Oncol. 2010 Nov;5(11):1734-40. doi: 10.1097/JTO.0b013e3181f0beca. Erratum in: J Thorac Oncol. 2011 Jun;6(6):1147.

PMID:
20881644
[PubMed - indexed for MEDLINE]
4.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

PMID:
21258250
[PubMed - indexed for MEDLINE]
5.

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S.

Clin Colorectal Cancer. 2012 Jun;11(2):143-50. doi: 10.1016/j.clcc.2011.12.001. Epub 2012 Jan 28.

PMID:
22285706
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.

Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL.

Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Epub 2013 Jul 13. Review. Erratum in: Int J Cancer. 2014 Jul 15;135(2):E2.

PMID:
23494461
[PubMed - indexed for MEDLINE]
7.

Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.

Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.

APMIS. 2013 Oct;121(10):954-66. doi: 10.1111/apm.12152. Epub 2013 Aug 29.

PMID:
23992303
[PubMed - indexed for MEDLINE]
8.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

PMID:
23374602
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.

Projetti F, Durand K, Chaunavel A, Léobon S, Lacorre S, Caire F, Bessède JP, Moreau JJ, Coulibaly B, Labrousse F.

Hum Pathol. 2013 Oct;44(10):2116-25. doi: 10.1016/j.humpath.2013.03.019. Epub 2013 Jun 20.

PMID:
23791006
[PubMed - indexed for MEDLINE]
10.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.

J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.

PMID:
19884556
[PubMed - indexed for MEDLINE]
Free Article
11.

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1045-55. doi: 10.1007/s00280-011-1586-z. Epub 2011 Feb 22.

PMID:
21340604
[PubMed - indexed for MEDLINE]
12.

Combined assessment of endothelial growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.

Takahashi N, Yamada Y, Taniguchi H, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y.

Arch Med Res. 2014 Jul;45(5):366-74. doi: 10.1016/j.arcmed.2014.05.004. Epub 2014 May 13.

PMID:
24830936
[PubMed - indexed for MEDLINE]
13.

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T.

J Thorac Oncol. 2006 Sep;1(7):629-34.

PMID:
17409929
[PubMed - indexed for MEDLINE]
14.

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.

Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G.

J Cancer Res Clin Oncol. 2014 May;140(5):737-48. doi: 10.1007/s00432-014-1626-2. Epub 2014 Mar 5.

PMID:
24595598
[PubMed - indexed for MEDLINE]
15.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

PMID:
19738166
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

PMID:
21163770
[PubMed - indexed for MEDLINE]
Free Article
17.

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.

Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S.

PLoS One. 2009 Oct 2;4(10):e7287. doi: 10.1371/journal.pone.0007287.

PMID:
19806185
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.

Neumann J, Wehweck L, Maatz S, Engel J, Kirchner T, Jung A.

Virchows Arch. 2013 Oct;463(4):509-23. doi: 10.1007/s00428-013-1450-0. Epub 2013 Aug 10.

PMID:
23934607
[PubMed - indexed for MEDLINE]
19.

Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.

Teng HW, Wang HW, Chen WM, Chao TC, Hsieh YY, Hsih CH, Tzeng CH, Chen PC, Yen CC.

J Surg Oncol. 2011 Jun;103(8):773-81. doi: 10.1002/jso.21852. Epub 2011 Jan 15.

PMID:
21240992
[PubMed - indexed for MEDLINE]
20.

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.

Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J.

PLoS One. 2011 Jan 20;6(1):e15980. doi: 10.1371/journal.pone.0015980.

PMID:
21283802
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk